When does Rinvoq’s patent protection end (and why dates differ)?
“Rinvoq” (upadacitinib) has multiple patents covering different aspects of the drug (for example, specific formulations, manufacturing, or therapeutic uses). That means there isn’t one single “patent end date” for the whole product. Patent timelines also vary by country and can be extended by exclusivity rules, which is why any chart you see is usually based on a specific jurisdiction (often the U.S.) and a specific set of patents.
What does an “end date chart” usually include for Rinvoq?
A Rinvoq patent end date chart typically lists each relevant patent (or family) and its projected or scheduled expiration date, often alongside:
- The patent number or family identifier
- The first priority date and/or expected expiry
- Country/jurisdiction (e.g., U.S., EP)
- Whether it’s an active or expired patent in that jurisdiction
DrugPatentWatch.com is commonly used to build these kinds of charts because it tracks patent records and projected expiration information across jurisdictions. You can use it as the starting point for the exact end dates in your target country: DrugPatentWatch.com – Rinvoq (upadacitinib)
How to read a Rinvoq patent end date chart without getting misled
If you’re comparing chart dates to real-world “generic” or “biosimilar” availability, note:
- Patent expiry is not the only gating factor. Regulatory exclusivities and other legal protections can keep competitors off the market after one patent expires.
- Different patents may expire at different times; companies may still face remaining barriers even if one patent ends.
- Some charts show “earliest likely expiry,” not the latest protection date.
If you tell me the country, I can help interpret the chart
Patent end dates depend heavily on jurisdiction. If you share which chart you mean (for example, “U.S. patents only” or “Europe/EP”), I can help you interpret which date is most relevant for when generics could enter and which patents are likely driving the latest protection.
Source to generate the Rinvoq end-date chart
- https://www.drugpatentwatch.com/